Cooley Advises GlobeImmune on Initial Public Offering

Broomfield, Colo. – August 7, 2014 – Cooley LLP announced today that it advised GlobeImmune, Inc. (GBIM) on its IPO. GlobeImmune is a biopharmaceutical company focused on the development of products designed for the treatment of cancer and infectious diseases based on its proprietary Tarmogen platform. The company trades on the NASDAQ Capital Market under the symbol "GBIM."

Thus far in 2014, Cooley has advised on 73 public offerings, including 37 completed IPOs.

About Cooley LLP

Cooley's attorneys solve legal issues for entrepreneurs, investors, financial institutions and established companies. Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and bet-the-company litigation, often where innovation meets the law.

Cooley has more than 750 lawyers across 11 offices in the United States and China.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.